Zynlonta (loncastuximab tesirine)
- Medicine Name: Zynlonta
- Generic Name: Loncastuximab Tesirine
- Dosage Form & Strength: Injection: 10 mg
- Manufactured By: ADC Therapeutics SA
Medical Uses
Zynlonta is a CD19-directed antibody and alkylating agent conjugate used for the treatment of adult patients with relapsed/refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, diffuse large B-cell lymphoma arising from low grade lymphoma, and high-grade B-cell lymphoma.
Recommended Dosage: The recommended dosage of zynlonta injection is administered as an intravenous infusion over 30 minutes on Day 1 of each cycle (every 3 weeks). The intravenous infusion of Zynlonta need to be administered as follows:
- 0.15 mg per kg every three weeks for 2 cycles.
- 0.075 mg per kg every three weeks for subsequent cycles.
Premedicate with dexamethasone 4 mg orally or intravenously twice daily for 3 days beginning the day prior to the treatment with Zynlonta.
Warning & Precautions
- Severe effusion and edema emerged in patients treated with zynlonta injection. Assess patients for new/worsening edema or effusions. Institute apt medical management for edema or effusions
- Treatment with zynlonta 10 mg injection can be responsible for causing severe myelosuppression, including thrombocytopenia, neutropenia, and anemia. Monitor complete blood counts (CBC) throughout therapy.
- Fatal and severe infections, including opportunistic infections, emerged in patients treated with Loncastuximab. Evaluate for any new or worsening signs/symptoms consistent with infection.
- Severe cutaneous reactions emerged in patients treated with loncastuximab 10 mg injection. Assess patients for new or worsening cutaneous reactions, including photosensitivity reactions.
- On behalf of its mechanism of action, Zynlonta can be responsible for causing embryo-fetal harm if administered to a pregnant woman because it contains a genotoxic compound (SG3199) and affects actively dividing cells.
Documentation & Availability
What documents are required to import ZYNLONTA to India?
ZYNLONTA (loncastuximab) injections can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patient’s diagnostic reports.
- Patient’s ID proof (issued by the Government of India).
How is the order confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from a doctor.
- Import permit if applicable.
Is ZYNLONTA available in India?
ZYNLONTA (loncastuximab injection) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
S S Healthcare (S S Healthcare) helps import cancer medicines on the named patient supply (NPS). S S Healthcare is facilitator providing input
- On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
ZYNLONTA can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit
S S Healthcare (S S Healthcare) can facilitate the supply of ZYNLONTA (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-7575883015 | Toll-Free No: +91-7575883015 or write us at sshealthcare1012@gmail.com for loncastuximab price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Sourcing & Delivery
S S Healthcare is able to source the ZYNLONTA (Cancer Treatment Medicines) from across the globe, and has the ability to supply. S S Healthcare offers its customers worldwide access to the best available treatment.
S S Healthcare is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
FAQ
What is the Generic Name for the trade name drug Zynlonta®?
Loncastuximab tesirine is Generic Name for the trade name drug Zynlonta®.
What is the Manufacturer Name of Zynlonta®?
Zynlonta® is manufactured by ADC Therapeutics SA.
Is Zynlonta® approved by the FDA?
Yes, Zynlonta® is approved by the FDA. Date of approval: April 23, 2021.
What is Zynlonta®?
Zynlonta is a monoclonal antibody conjugate medication specifically designed to treat patients with relapsed or refractory diffuse large B-cell lymphoma.
What is the dosage and form of Zynlonta® supplied?
Zynlonta® is supplied as Injection: 10 mg of loncastuximab tesirine-lpyl as a white to off-white lyophilized powder in a single-dose vial for intravenous administration.
What are the most common side effects due to Zynlonta®?
Most common side effects due to Zynlonta® include: skin rash, feeling tired or weak, swelling, nausea, muscle or joint pain, increase in blood sugar (hyperglycemia), and changes in certain blood or laboratory tests.
What is the best price of Zynlonta® in India?
The zynlonta price in India is very reasonable. In order to procure this B-cell lymphoma medication authentically, you can call or WhatsApp +91-7575883015 or send mail to sshealthcare1012@gmail.com.
What are the storage conditions of Zynlonta®?
Store refrigerated at temperature 2-8°C (36-46°F) in the original carton in order to protect from the light. Do not freeze. Do not shake.
What are the Highlights of prescribing information for Zynlonta®?
Click Here to download full Zynlonta prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Email Address
Sshealthcare1012@gmail.com
+91 7575883015
Landline
079 48916267
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners, and S S Healthcare does not lay any claim on them. We only provide information.
